Physician profile
Augusto E Villegas
NPI 1003804485
$94,087.38
in general payments reported to CMS, 2019-2025
86 companies · $3,939 in 2025
The $3,939 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $27K · 2021: $12K · 2022: $8,067 · 2023: $4,011 · 2024: $2,300 · 2025: $3,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,711 · Consulting Fee: $3,400 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,710.74 |
| Consulting Fee | $3,400.00 |
| Education | $138.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $62,493.68 | 2019-2025 | Enhertu, Imfinzi |
| Seagen INC. | $7,360.95 | 2019-2023 | Tukysa, Tivdak |
| Astrazeneca Uk Limited | $2,775.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $2,689.04 | 2019-2025 | |
| Genzyme Corporation | $2,317.40 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $2,263.08 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,635.19 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Amgen INC. | $1,150.67 | 2019-2025 | Blincyto, Kyprolis, Lumakras |
| Merck Sharp & Dohme LLC | $1,070.67 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $1,060.29 | 2019-2023 | |
| Pfizer INC. | $897.45 | 2019-2025 | |
| Celgene Corporation | $520.69 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $473.46 | 2019-2025 | Tecentriq, Polivy, Itovebi |
| Janssen Biotech, INC. | $459.23 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Eisai INC. | $362.16 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $353.76 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $353.74 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Alexion Pharmaceuticals, INC. | $341.15 | 2021-2024 | Ultomiris |
| Astellas Pharma US INC | $335.81 | 2019-2025 | Xospata, Padcev, Xtandi |
| Incyte Corporation | $315.24 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $285.63 | 2019-2024 | Alunbrig, Ninlaro, Fruzaqla |
| Abbvie INC. | $246.53 | 2020-2025 | Venclexta |
| Lilly USA, LLC | $239.78 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Kite Pharma, INC. | $229.33 | 2021-2025 | Yescarta |
| Daiichi Sankyo INC. | $221.11 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Exelixis INC. | $219.93 | 2019-2024 | Cabometyx |
| Array Biopharma INC | $215.86 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Jazz Pharmaceuticals INC. | $176.68 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.77 | 2019-2024 | Libtayo |
| Taiho Oncology, INC. | $163.09 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $151.21 | 2019-2023 | Somatuline Depot, Onivyde |
| Emd Serono, INC. | $134.34 | 2019-2023 | Bavencio |
| Immunocore Limited | $120.76 | 2025 | Kimmtrak |
| Novocure INC. | $114.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.86 | 2020-2025 | |
| Tersera Therapeutics LLC | $110.49 | 2023-2025 | Zoladex |
| Mirati Therapeutics, INC. | $104.23 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $96.31 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $90.58 | 2019-2020 | |
| Beigene USA, INC. | $87.41 | 2021-2024 | Brukinsa |
| Morphosys, US INC. | $80.79 | 2022-2024 | Monjuvi |
| G1 Therapeutics, INC. | $80.68 | 2022-2023 | Cosela |
| Global Blood Therapeutics, INC. | $79.49 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $69.80 | 2022-2024 | |
| Epizyme, INC. | $64.65 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $61.51 | 2019-2023 | Provenge |
| Adc Therapeutics America, INC. | $60.82 | 2021-2025 | |
| Tesaro, INC. | $57.98 | 2019 | |
| Sobi, INC | $49.71 | 2025 | |
| Adaptive Biotechnologies Corporation | $48.53 | 2022-2025 | Clonoseq |
| Foundation Medicine, INC. | $48.06 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $48.05 | 2020-2022 | |
| Octapharma USA, INC. | $47.46 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Progenics Pharmaceuticals, INC. | $44.93 | 2023 | Pylarify |
| Dova Pharmaceuticals | $44.04 | 2019-2020 | |
| Emmaus Medical, INC. | $39.77 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $38.47 | 2024 | Cosela |
| Deciphera Pharmaceuticals INC. | $37.73 | 2022-2023 | Qinlock |
| Blueprint Medicines Corporation | $36.53 | 2020-2025 | Ayvakit |
| Tg Therapeutics, INC. | $34.10 | 2021-2022 | |
| Napo Pharmaceuticals INC | $31.97 | 2024 | Gelclair Concentrated Oral Gel |
| Beone Medicines USA, INC. | $30.58 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $30.30 | 2021 | |
| Csl Behring | $28.60 | 2023 | Idelvion, Afstyla |
| Secura Bio, INC. | $26.32 | 2020-2022 | |
| Pharmaessentia USA Corporation | $25.95 | 2024 | Besremi |
| Aurobindo Pharma USA, INC. | $25.94 | 2019-2020 | |
| Stemline Therapeutics INC. | $25.41 | 2024 | Orserdu |
| Sanofi-Aventis U.S. LLC | $24.21 | 2020 | |
| Fennec Pharmaceuticals, INC. | $24.07 | 2024 | Pedmark |
| Lundbeck LLC | $22.67 | 2020 | |
| Sirtex Medical INC | $22.55 | 2019-2020 | |
| Blue Earth Diagnostics | $20.83 | 2021 | |
| Cti Biopharma Corp. | $20.58 | 2023 | Vonjo |
| Lexicon Pharmaceuticals, INC. | $17.91 | 2019 | |
| Clovis Oncology, INC. | $16.15 | 2020 | |
| Iovance Biotherapeutics, INC. | $15.45 | 2025 | Amtagvi |
| Sun Pharmaceutical Industries INC. | $15.25 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.72 | 2020 | |
| Agios Pharmaceuticals, INC. | $13.61 | 2020 | |
| Puma Biotechnology, INC. | $13.43 | 2020 | |
| Myovant Sciences INC. | $11.92 | 2022 | |
| Veracyte, INC. | $0.85 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $433Reblozyl $313Opdivo $294Tukysa $259Xtandi $238Enhertu $224Lenvima $196Lynparza $195Talzenna $189Elrexfio $188Adcetris $178Rybrevant $170Orgovyx $166Ultomiris $155Scemblix $149Braftovi $149Mektovi $149Fabhalta $148Monjuvi $148Sarclisa $147Jaypirca $135Ibrance $126Trodelvy $122Ojjaara $121Kimmtrak $121Yescarta $116Zepzelca $115Verzenio $113Zoladex $110Padcev $109Bosulif $104Krazati $104Tibsovo $96.31Libtayo $90.85Tecentriq $88.62Lorbrena $86.64Pluvicto $84.21Brukinsa $82.89Opdualag $82.66Cosela $77.11Inlyta $76.55Darzalex $76.31Xospata $75.38Vonjo $70.29Cabometyx $69.97Xalkori $69.24Inqovi $65.25Lonsurf $65.25Venclexta $64.61Elahere $62.43Imbruvica $61.51Kisqali $56.97Ayvakit $55.25Pemazyre $49.15Jemperli $45.52Pylarify $44.93Jakafi $43.32Epkinly $42.60Welireg $41.31Promacta $38.83Piqray $38.21Bavencio $38.15Zynyz $37.72Tivdak $37.10Alunbrig $35.69Comirnaty $34.86Gelclair Concentrated Oral Gel $31.97Tasigna $30.42Polivy $30.32Vijoice $30.21Nubeqa $29.59Xofigo $29.59Blincyto $29.57Kyprolis $29.57Clonoseq $29.47Paxlovid $29.16Afstyla $28.60Idelvion $28.60Provenge $27.10Besremi $25.95Orserdu $25.41Ninlaro $25.03Itovebi $24.82Datroway $24.57Tecvayli $24.41Talvey $24.41Panzyga $24.21Pedmark $24.07Blenrep $23.65Alecensa $23.50Fruzaqla $23.37Octagam Immune Globulin (Human) $23.25Zejula $23.17Retevmo $21.99Imfinzi $21.35Idhifa $19.31Lumakras $19.19Fotivda $19.13Vanflyta $17.43Mekinist $16.35
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Villegas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.